Efficacy of increased-dose erlotinib for central nervous system metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation by Togashi, Yosuke et al.
SHORT COMMUNICATION
Efﬁcacy of increased-dose erlotinib for central nervous system
metastases in non-small cell lung cancer patients with epidermal
growth factor receptor mutation
Yosuke Togashi • Katsuhiro Masago • Masahide Fukudo • Yasuhiro Tsuchido •
Chiyuki Okuda • Young Hak Kim • Yasuaki Ikemi • Yuichi Sakamori •
Tadashi Mio • Toshiya Katsura • Michiaki Mishima
Received: 20 April 2011/Accepted: 1 June 2011/Published online: 17 June 2011
 The Author(s) 2011. This article is published with open access at Springerlink.com
Abstract
Purpose Recent reports indicate that refractory central
nervous system (CNS) metastases of non-small cell lung
cancer (NSCLC) are improved by high-dose geﬁtinib or
erlotinibadministration.WedescribeaJapanesewomanwith
NSCLC and CNS metastases who was resistant to 75 mg
daily erlotinib, but the metastases were improved by 150 mg
daily erlotinib. We investigated the plasma and CSF con-
centrations of erlotinib at eachdoseas wellas the correlation
between the plasma and CSF concentrations of erlotinib.
Methods Including this patient, we administered 150 mg
erlotinib daily to nine NSCLC patients with CNS metas-
tases and measured the plasma and CSF concentrations just
before administration on day 8. The concentrations were
determined using high-performance liquid chromatography
with ultraviolet detection.
Results The plasma and CSF concentrations of erlotinib
at a dose of 75 mg were 433 and 14 nM, respectively. The
plasma and CSF concentrations of erlotinib at a dose of
150 mg were increased to 1,117 and 44 nM, respectively.
The mean ± standard deviation of CSF concentrations and
penetration rates were 106 ± 59 nM and 4.5 ± 1.5%,
respectively. There was a good correlation (R
2 = 0.84)
between plasma and CSF concentrations (P = 0.0005).
Conclusions This study indicates that CSF concentrations
of erlotinib depend on its plasma concentration. As seen in
this patient, high CSF concentrations of erlotinib can be
achieved by high-dose administration, and this ﬁnding
suggests the efﬁcacy of high-dose administration, espe-
cially to refractory CNS metastases of NSCLC patients.
Keywords Non-small cell lung cancer  Epidermal
growth factor receptor  Tyrosine kinase inhibitor 
Erlotinib  Central nervous system metastasis 
Cerebrospinal ﬂuid
Introduction
Patients with non-small cell lung cancer (NSCLC) who
have somatic activating mutations of the epidermal growth
factor receptor (EGFR) gene (EGFR mutations) generally
respond to EGFR-tyrosine kinase inhibitors (EGFR-TKIs,
e.g., geﬁtinib and erlotinib) [1, 2]. Nevertheless, the
majority of these patients experience eventual disease
progression, despite an initial dramatic response to treat-
ment. The central nervous system (CNS) is a common site
of recurrence, which is thought to be due to penetration of
the agents into the CNS [3, 4]. A previous report described
refractory CNS metastases of NSCLC that were improved
by high-dose geﬁtinib [5]. Several cases in which CNS
metastases resistant to geﬁtinib were improved by erlotinib
have been also reported [6]. In addition, in several articles,
intermittent, high-dose erlotinib improved CNS metastases
that were resistant to continuous, normal-dose erlotinib [7–
9]. These challenges are based on the hypothesis that high
cerebrospinal ﬂuid (CSF) concentrations may be achieved
by high-dose administration of EGFR-TKIs, with higher
CSF concentrations achieved by erlotinib compared with
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of erlotinib and its penetration rates in four NSCLC
patients with CNS metastases [10]. In this article, we
describe a Japanese woman with NSCLC and EGFR
mutation having CNS metastases that are resistant to
75 mg daily erlotinib. The metastases were subsequently
improved by 150 mg daily erlotinib. We investigated the
plasma and CSF concentrations of erlotinib at each dose.
Furthermore, including previous data, we investigated the
correlation between plasma and CSF concentrations.
Patients and methods
Patients
A 66-year-old Japanese woman was diagnosed with
advanced lung adenocarcinoma and EGFR mutation
(L858R) 3 years prior. Erlotinib had been administered as
fourth line of treatment. Before the initiation of erlotinib,
the patient had no CNS metastases. Although partial
response (PR) was achieved, the erlotinib dose was reduced
from 150 to 75 mg daily due to grade 3 fatigue. After
progression-free survival (PFS) of 12 months, the patient
experienced recurrent CNS metastases. The plasma and
CSF concentrations of erlotinib just before administration
of the 75-mg dose were 433 and 14 nM, respectively. The
patient received whole-brain radiotherapy (WBRT), but the
CNS metastases did not improve (Fig. 1a). The dose was
subsequently increased to 150 mg daily; the plasma and
CSF concentrations just before administration of erlotinib
on day 8 erlotinib were 1,117 and 44 nM, respectively.
Four weeks after the initiation of 150 mg administration of
erlotinib, CNS metastases improved (Fig. 1b).
We previously reported the plasma and CSF concen-
trations of four NSCLC patients with CNS metastases
Fig. 1 Brain magnetic
resonance imaging (MRI) in the
66-year-old Japanese female
patient. a Brain MRI after
whole-brain radiotherapy
demonstrated stable brain
metastases (arrowheads). At
this point, 75 mg daily erlotinib
was administered. b Four weeks
after initiation of 150 mg daily
erlotinib, the metastases were
improved (arrowheads)
Table 1 Patient characteristics
Cases Age (yr) Sex PS Histology EGFR gene Smoking
status
Previous chemotherapy
regimen
Previous geﬁtinib
(length of PFS)
Previous
WBRT
1 59 F 3 Ad NE Never 3 Yes (10 months) Yes
2 82 F 4 Ad Wild type Never 0 No No
3 70 F 3 Ad Wild type Never 1 No Yes
4 86 F 3 Ad Ex 21; L858R Never 1 Yes (7 months) No
5 67 F 1 Ad Ex 21; L858R Never 1 No No
6 72 M 0 Ad Ex 21; L858R Former 1 No No
7 81 M 1 Ad Ex 19 deletion Former 1 Yes (46 months) Yes
8 85 F 2 Ad Ex 21; L858R Never 1 No Yes
a 66 F 1 Ad Ex 21; L858R Never 3 No Yes
PS performance status, EGFR epidermal growth factor receptor, PFS progression-free survival, WBRT whole-brain radiotherapy, F female,
M male, Ad adenocarcinoma, NE not evaluated, Never never-smoker, Former former-smoker
a A 66-year-old Japanese female patient in this study
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123(cases 1–4) [10]. In addition to these patients, we investi-
gated the plasma and CSF concentrations of four other
NSCLC patients with CNS metastases (cases 5–8)
(Table 1).
Methods
Blood and CSF samples were obtained just before the
administration of 150 mg erlotinib on day 8 when steady-
state plasma concentrations of erlotinib were assumed to be
achieved. Plasma and CSF concentrations of erlotinib were
determined using high-performance liquid chromatography
with ultraviolet detection as previously reported [11].
Before the collection of samples and analysis, we obtained
written informed consent from all patients.
Statistical analysis
Linear regression was performed on the data in Fig. 2 by
ﬁtting a straight line. The R
2 value was used to measure the
strength of the relationship between the plasma and CSF
concentrations of erlotinib. The 150-mg daily erlotinib data
fromthis66-year-oldJapanesefemalepatientwereanalyzed,
and the 75-mg daily erlotinib data were excluded. Linear
regression analysis, performed using JMP 8 software (SAS
Institute, Cary, NC, USA), was two-tailed, and P values less
than 0.05 were considered statistically signiﬁcant.
Results
The clinical characteristics of all patients (n = 9) are
summarized in Table 1. In CNS lesions, 7 of the 9 patients
achieved PR (78%) and 5 of the 6 patients with EGFR
mutations achieved PR (83%). Geﬁtinib was administered
to three patients prior to erlotinib therapy; these patients
achieved PR but had CNS recurrence after a long PFS of
more than 6 months. Two of these three patients achieved
PR after erlotinib therapy in spite of geﬁtinib resistance.
The plasma and CSF concentrations are summarized in
Table 2. The mean ± standard deviation (SD) of CSF
concentrations and penetration rates were 106 ± 59 nM
and 4.5 ± 1.5%, respectively. As seen in Fig. 2, there was
a good correlation (R
2 = 0.84) between plasma and CSF
concentrations (P = 0.0005).
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Fig. 2 Correlation between plasma concentrations and cerebrospinal
ﬂuid (CSF) concentrations of erlotinib. A good correlation
(R
2 = 0.84) was demonstrated (P = 0.0005)
Table 2 Plasma and cerebrospinal ﬂuid concentrations of erlotinib, and central nervous system metastases response
Case Plasma
concentration (nM)
CSF
concentration (nM)
Penetration
rate (%)
CNS response
a
1 2,082 98 4.7 Partial response
2 4,059 202 5.0 Stable disease
3 4,922 156 3.2 Partial response
4 544 42 7.7 Stable disease
5 2,575 98 3.8 Partial response
6 1,314 47 3.5 Partial response
7 1,886 98 5.2 Partial response
8 5,376 172 3.2 Partial response
(75 mg erlotinib)
b 433 14 3.3 Progressive disease
(150 mg erlotinib)
b 1,117 44 3.9 Partial response
Mean ± SD
c 2,653 ± 1,734 106 ± 59 4.5 ± 1.5
CSF cerebrospinal ﬂuid, CNS central nervous system, SD standard deviation
a Responses were assessed by magnetic resonance imaging with use of the Response Evaluation Criteria in Solid Tumor version 1.1
b A 66-year-old Japanese female patient in this study
c We analyzed the mean ± SD from all data except for the data from the 66-year-old Japanese female patient at a dose of 75 mg erlotinib
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This study demonstrated that there is a good correlation
(R
2 = 0.84) between plasma and CSF concentrations of
erlotinib (P = 0.0005), which indicates that high CSF
concentrations can be achieved by high plasma concen-
trations. That is, high CSF concentrations can be achieved
by high-dose erlotinib administration. CNS metastases of
the 66-year-old Japanese female patient responded to
150 mg daily erlotinib despite resistance to 75 mg daily
erlotinib, likely because of higher CSF concentrations.
There are several reports based on the hypothesis that high
CSF concentrations may be achieved by high-dose erloti-
nib administration [5–9], and our study supports this
hypothesis.
The mean ± SD of CSF penetration rates were
4.5 ± 1.5%, and this result was similar to that of recent
another study [12]. However, the rates of our study were
ranged from 3.2 to 7.7% and those of another study ranged
from 2.5 to 13.3%, which indicates that there seem to be
difference in the penetration rate between individuals.
Recently, it has been reported that some transporters
restrict brain penetration of erlotinib [13, 14]. Polymor-
phisms of these transporters can be associated with this
individual difference in the penetration rate.
Since systemic chemotherapy is thought to play a lim-
ited role in CNS metastases because of the belief that the
brain is a pharmacological sanctuary, patients with NSCLC
who showed initial good responses to EGFR-TKIs often
had recurrent CNS metastases. Considering CSF concen-
trations, high-dose EGFR-TKIs can be effective for such
refractory metastases. Furthermore, the association
between CNS responses/recurrence and CSF concentra-
tions should be investigated in the future.
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